What is Retinitis Pigmentosa Market?
Retinitis pigmentosa is a group of rare, genetic disorders that involve a breakdown and loss of cells in the retina, a light-sensitive tissue that lines the back of the eye, which can lead to loss of sight. The common symptom for retinitis pigmentosa involves difficulty seeing at night and a loss of side (peripheral) vision. It is a rare disorder that is passed from parent to child and only 1 out of every 4,000 people get it. The factors such as Increased Prevalence of Retinitis Pigmentosa and Increased Number of Diagnostic Centres are driving the global retinitis pigmentosa market.
The market study is being classified and major geographies with country level break-up.
ReNeuron Group (United Kingdom), Amarantus BioScience Holdings, Inc. (United States), Ocugen, Inc. (United States), ReGenX Biosciences, LLC (United States), Sucampo Pharmaceuticals, Inc. (United States), Orphagen Pharmaceuticals, Inc. (United States), Second Sight Medical Products, Inc. (United States), Novartis (Switzerland) and MeiraGTx Limited (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are GenSight Biologics S.A. (France) and Allergan, Inc. (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Retinitis Pigmentosa market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Retinitis Pigmentosa market by Type, Application and Region.
On the basis of geography, the market of Retinitis Pigmentosa has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Retinitis Pigmentosa
- Increased Number of Diagnostic Centres
- Advancements in the Medical Science
- Increased Awareness among People About Healthy Lifestyle
- Side Effects of the Drugs used for Retinitis Pigmentosa
- Growth in the Healthcare Industry
- Increased Research and Development Activities
- Stringent Rules and Regulations
Market Leaders and some development strategies
In September 2019, Ocugen, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies that address rare and underserved eye diseases, has announced the completion of its merger with Histogenics Corporation, and the change of the combined company’s name to “Ocugen, Inc.”
Key Target AudienceRetinitis Pigmentosa Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase